Status:

COMPLETED

Effect of N-acetylcysteine (NAC) on Hydrogen Sulfide (H2S) in Chronic Kidney Disease (CKD)

Lead Sponsor:

A.C. Abrahams

Conditions:

Chronic Kidney Disease

Chronic Kidney Failure

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

Cardiovascular morbidity and mortality is high in CKD patients. Nitric oxide (NO) deficiency plays a crucial role in progression of CKD. This leads to endothelial dysfunction, hypertension, and inflam...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Healthy volunteers:
  • Adult (\> 18 years and older)
  • Healthy, as assessed by medical history, blood pressure, plasma creatinine, and urine dipstick
  • No medication use
  • CKD patient:
  • Adult (\> 18 years and older)
  • CKD stage 3-4 (GFR 15-60 ml/min)
  • Hemodialysis patient:
  • Adult (\> 18 years and older)
  • Hemodialysis patient
  • Peritoneal dialysis patient:
  • Adult (\> 18 years and older)
  • Peritoneal dialysis patient
  • Exclusion criteria:
  • Unable to give informed consent
  • Hypersensitivity to N-acetylcysteine
  • Pregnancy

Exclusion

    Key Trial Info

    Start Date :

    July 1 2011

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    December 1 2011

    Estimated Enrollment :

    28 Patients enrolled

    Trial Details

    Trial ID

    NCT01232257

    Start Date

    July 1 2011

    End Date

    December 1 2011

    Last Update

    October 26 2012

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    UMC Utrecht

    Utrecht, Netherlands, 3584 CX